This section gives an overview of various exit strategies.

GNX 5: M&A in COVID-19 Environment and Beyond – Keep Your Perspective
GNX 6: Why Licensing and Partnering Activity Should Remain Steady in 2020
GNX 4: Partnering Essentials: Identifying and Engaging with Potential Licensees
GNX 3: Will the latest diagnostic technologies change clinical practice?
GNX 2: Interpreting and Negotiating Deal Terms for a Licensing Agreement
GNX 1: Dancing with the Dragon: Cross-border Transactions between China and the World
GNP 14: IP Licensing: what does this involve and what effects can it have on IP Filing and Exploitation Strategies in Life Sciences?
GNP 5: IP Rights – Best Practice for M&A
GNT 59: Corporation Tax Deductions for Employee Share Schemes
GNT 56: Entrepreneurs’ Relief
GNT 39: Demergers
GNT 4: Deferred Consideration
GNT 3: Licensing
GNT 29: Tax Model

Register to receive up-to-date information and advice on tax developments within your industry.